The significance of the correlation between the cell proliferative index KI-67 and the human epidermal growth factor HER2 in breast cancer patients who received neoadjuvant therapy.
Abstract
Objective. Evaluation of the value of HER2 and Ki-67 expression and determination of their mutual correlation within two-factor analysis models in patients with a pathohistologically confirmed diagnosis of breast cancer, who received neoadjuvant therapy.
Methods. The retrospective study includes all breast cancer patients who underwent neoadjuvant and surgical therapy at Serbia's Institute of Oncology and Radiology between 2017 and 2019. HER2 positive status was defined either as a value of 3+ by immunohistochemical analysis or as an amplification of the HER2 gene by in situ hybridization, for values of 2+. Relevant statistical methods were used to test statistical differences: chi-square test, Mann-Whitney U test, and Kruskall Wallis H-test.
Results. In the analyzed group of patients, the most frequently determined value of HER2 expression is 1+. By testing the correlation of the Ki-67 cell proliferative index value with HER2 and testing the differences between groups by post hoc analysis on the material obtained by preoperative, core needle biopsy, a statistically significant difference was determined (H=9.020, p=0.029), especially between the HER2 groups (1+) and (3+) (highly statistically significant difference (U=863.5, p=0.005)) and HER2 (2+) and (3+) (statistically significant difference (U=907, p=.036)).
Conclusion. The results of our study indicate that the degree of HER2 expression is in a statistically significant and positive correlation with the values of the cell proliferative index Ki-67, which correlates with the results of previous studies and oncological practice, which confirmed that excessive amplification or expression of HER2 is associated with the degree of malignancy and poor prognosis of breast cancer.
References
2. Arens N, Bleyl U, Hildenbrand R. HER2/neu, p53, Ki67, and hormone receptors do not change during neoadjuvant chemotherapy in breast cancer. Virchows Archiv. 2005;446(5):489-496. doi:10.1007/s00428-005-1244-0
3. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2. New England Journal of Medicine. 2001;344(11):783-792. doi:10.1056/NEJM200103153441101
4. Klapper LN, Glathe S, Vaisman N, et al. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proceedings of the National Academy of Sciences. 1999;96(9):4995-5000. doi:10.1073/pnas.96.9.4995
5. Avci N, Deligonul A, Tolunay S, et al. Neoadjuvant chemotherapy-induced changes in immunohistochemical expression of estrogen receptor, progesterone receptor, HER2, and Ki-67 in patients with breast cancer. J BUON. 2015;20(1):45-49.
6. Nahed AS, Shaimaa MY. Ki-67 as a prognostic marker according to breast cancer molecular subtype. Cancer Biol Med. 2016;13(4):496. doi:10.20892/j.issn.2095-3941.2016.0066
7. Dowsett M, Nielsen TO, A’Hern R, et al. Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group. JNCI Journal of the National Cancer Institute. 2011;103(22):1656-1664. doi:10.1093/jnci/djr393
8. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 1983;31(1):13-20. doi:10.1002/ijc.2910310104
9. Ragab HM, Samy N, Afify M, El Maksoud NA, Shaaban HM. Assessment of Ki-67 as a potential biomarker in patients with breast cancer. Journal of Genetic Engineering and Biotechnology. 2018;16(2):479-484. doi:10.1016/j.jgeb.2018.03.002
10. Sestak I, Buus R, Cuzick J, et al. Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor–Positive Breast Cancer. JAMA Oncol. 2018;4(4):545. doi:10.1001/jamaoncol.2017.5524
11. Živković Ognjen, Milićević Anđela, Petrović Ivana, et al. INVERZNA KORELACIJA IZMEĐU VREDNOSTI PROLIFERATIVNOG ĆELIJSKOG INDEKSA KI-67 I VREDNOSTI STEROIDNIH RECEPTORA KOD PACIJENTKINJA SA KARCINOMOM DOJKE. MEDICINSKI ČASOPIS. 2024;58(1) IN PRESS. doi:https://doi.org/10.5937/mckg58-50172
12. Wolff AC, Hammond MEH, Allison KH, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. Journal of Clinical Oncology. 2018;36(20):2105-2122. doi:10.1200/JCO.2018.77.8738
13. Payandeh M, Shahriari-Ahmadi A, Sadeghi M, Sadeghi E. Correlations between HER2 Expression and Other Prognostic Factors in Breast Cancer: Inverse Relations with the Ki-67 Index and P53 Status. Asian Pacific Journal of Cancer Prevention. 2016;17(3):1015-1018. doi:10.7314/APJCP.2016.17.3.1015
14. Yoshioka T, Hosoda M, Yamamoto M, et al. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer. Breast Cancer. 2015;22(2):185-191. doi:10.1007/s12282-013-0474-2
15. Madani SH, Payandeh M, Sadeghi M, Motamed H, Sadeghi E. The correlation between Ki-67 with other prognostic factors in breast cancer: A study in Iranian patients. Indian Journal of Medical and Paediatric Oncology. 2016;37(02):95-99. doi:10.4103/0971-5851.180136
16. Dang Cong T, Nguyen Thanh T, Nguyen Phan QA, Hoang Thi AP, Nguyen Tran BS, Nguyen Vu QH. Correlation between HER2 Expression and Clinicopathological Features of Breast Cancer: A Cross- Sectional Study in Vietnam. Asian Pacific Journal of Cancer Prevention. 2020;21(4):1135-1142. doi:10.31557/APJCP.2020.21.4.1135
17. Kanyilmaz G, Benli Yavuz B, Aktan M, Karaagac M, Uyar M, Findik S. Prognostic Importance of Ki-67 in Breast Cancer and Its Relationship with Other Prognostic Factors. Eur J Breast Health. 2019;15(4):256-261. doi:10.5152/ejbh.2019.4778
18. Camerini A, Donati S, Viacava P, et al. Evaluation of HER2 and p53 expression in predicting response to docetaxel-based first-line chemotherapy in advanced breast cancer. Journal of Experimental & Clinical Cancer Research. 2011;30(1):38. doi:10.1186/1756-9966-30-38
19. Kamranzadeh H, Ardekani R, Kasaeian A, et al. Association between Ki-67 expression and clinicopathological features in prognosis of breast cancer: A retrospective cohort study. Journal of Research in Medical Sciences. 2019;24(1):30. doi:10.4103/jrms.JRMS_553_18
20. NISHIMURA R, OSAKO T, NISHIYAMA Y, et al. Prognostic significance of Ki-67 index value at the primary breast tumor in recurrent breast cancer. Mol Clin Oncol. 2014;2(6):1062-1068. doi:10.3892/mco.2014.400